Xeris Biopharma Holdings, Inc. (XERS)

Market Cap	305.41M
Revenue (ttm)	171.36M
Net Income (ttm)	-64.40M
Shares Out	148.26M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,368,880
Open	2.160
Previous Close	2.170
Day's Range	2.030 - 2.165
52-Week Range	1.460 - 3.260
Beta	1.32
Analysts	Strong Buy
Price Target	4.63 (+124.76%)
Earnings Date	Aug 6, 2024

About XERS

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 377
• Stock Exchange: NASDAQ
• Ticker Symbol: XERS

Financial Performance

In 2023, XERS's revenue was $163.91 million, an increase of 48.68% compared to the previous year's $110.25 million. Losses were -$62.26 million, -34.23% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for XERS stock is "Strong Buy." The 12-month stock price forecast is $4.63, which is an increase of 124.76% from the latest price.

Price Target

$4.63

(124.76% upside)

Analyst Consensus: Strong Buy